---
title: "Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688050.SH.md"
symbol: "688050.SH"
name: "Eyebright Medical Technology (Beijing) Co., Ltd."
industry: "Health Care Supplies"
datetime: "2026-05-20T16:49:12.834Z"
locales:
  - [en](https://longbridge.com/en/quote/688050.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688050.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688050.SH.md)
---

# Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH)

## Company Overview

Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for ophthalmic surgery, refractive error correction, and optometry consumption.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | CN Market |
| Website | [www.ebmedical.com](https://www.ebmedical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.42)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 40 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.60% |  |
| Net Profit YoY | -29.93% |  |
| P/B Ratio | 3.20 |  |
| Dividend Ratio | 0.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9193303799.84 |  |
| Revenue | 1526472717.57 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.97% | B |
| Profit Margin | 17.38% | A |
| Gross Margin | 61.48% | A |
| Revenue YoY | 4.60% | C |
| Net Profit YoY | -29.93% | D |
| Total Assets YoY | 34.75% | A |
| Net Assets YoY | 17.28% | B |
| Cash Flow Margin | 117.92% | C |
| OCF YoY | 4.60% | C |
| Turnover | 0.37 | C |
| Gearing Ratio | 34.38% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Eyebright Medical Technology (Beijing) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.60%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9193303799.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1526472717.57",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.97%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "17.38%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "61.48%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "4.60%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-29.93%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "34.75%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.28%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "117.92%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "4.60%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.38%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 33.70 | 15/40 | 37.45 | 34.74 | 32.27 |
| PB | 3.12 | 29/40 | 5.16 | 4.41 | 3.89 |
| PS (TTM) | 5.86 | 19/40 | 9.62 | 8.39 | 7.40 |
| Dividend Yield | 0.76% | 27/40 | 0.63% | 0.56% | 0.46% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Snibe (300832.SZ) | A | D | C | A | C | B |
| 02 | Winner Medical (300888.SZ) | B | B | B | B | B | B |
| 03 | Fuerjia (301371.SZ) | B | C | D | A | B | B |
| 04 | MTM (688029.SH) | B | B | B | A | B | B |
| 05 | Endovastec (688016.SH) | A | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-10T16:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 1 | 17% |
| Hold | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 46.15 |
| Highest Target | 90.00 |
| Lowest Target | 60.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688050.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688050.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688050.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688050.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**